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Warfarin and other medications
There may be two forms of interactions 
between warfarin and other drugs:1
a) Pharmacokinetic interactions 
 which include:
• Alteration in absorption: This may 
involve an alteration in absorption of 
either vitamin K or warfarin. It may 
include alteration of gut flora causing 
reduced availability of vitamin K (eg 
some broad spectrum antibiotics)2, 
or binding with warfarin resulting in 
reduced absorption (eg cholestyramine 
or colestipol).2, In the latter case, 
separating the two drugs by -6 hours 
may help overcome this interaction.
• Interference with warfarin metabolism: 
Drugs may inhibit or induce cytochrome 
(CYP) enzymes involved in the 
metabolism of warfarin and may therefore 
alter the plasma concentrations of 
warfarin.  Warfarin is a racemic mixture 
with the (S) form being five times more 
potent than the (R) form. Hepatic 
metabolism involves separate pathways, 
and drugs may exhibit stereoselectivity 
by inhibiting one form but not the 
other.  The (S) form is metabolized by 
CYP2C9 and the R-isomer metabolised 
by CYP1A2, CYP2C19 and CYPA.5 
Drugs which interfere with CYP2C9 have 
a more clinically significant effect on 
anticoagulation. Examples of inducers 
include rifampicin and barbiturates 
while metronidazole is a potent enzyme 
inhibitor.2, 
• Displacement from protein binding sites:  
The clinical significance of reductions in 
plasma protein binding by interacting 
drugs has been debated. Protein-bound 
warfarin is in equilibrium with free 
warfarin such that around 99% is bound; 
displacement of warfarin from serum 
proteins will result in an increased 
amount of free drug, making it available 
to move to the intracellular sites of 
action and to be excreted. The effect is 
usually described as transitory and said 
only rarely to require warfarin dosage 
adjustment because the increased free 
drug is metabolised or excreted and a 
new equilibrium established.5,6
b) Pharmacodynamic interactions:
 Some drugs affect platelet function by 
reducing platelet aggregation. Thus, 
even though these drugs do not affect 
the INR, they may be associated with 
an increased risk of bleeding. Examples 
include aspirin, dipyridamole, clopidogrel 
and ticlopidine.2, 
Warfarin and alternative therapies
Several alternative therapies may have 
the potential to interact with warfarin. 
However, due to a lack of available 
information, the clinical significance of 
potential interactions is often unknown 
since most information is related to in 
vitro data, case reports and theoretical 
interactions. Overall, patients on warfarin 
should be advised not to self-treat with 
such therapies. Often, patients do not 
mention herbal medications to their health 
care professional believing that these are 
safe and will not interact with conventional 
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Maintaining a patient within a therapeutic international 
normalized ratio (INR) is the main aim of treatment with 
warfarin.  Anticoagulation above or below the therapeutic window 
may result in bleeding or thrombosis respectively. This is made 
more complex by the numerous factors that may affect warfarin 
management including other drugs, diet and disease. This review 
aims to highlight factors that may affect therapy with oral 
anticoagulants (Figure 1). A sound knowledge of such factors 
ensures safe administration of warfarin. 
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affect warfarin levels.1 Chronic alcoholics 
may experience a diminished effect from 
warfarin due to stimulation of hepatic 
metabolism by alcohol. In the case of 
‘binge’ drinking, there may be an increase in 
effect of warfarin due to the inability of the 
liver to metabolise and synthesise clotting 
factors. Alcohol is considered safe in people 
with normal liver function provided there is 
an intake no greater than 2 units daily.1
Other factors affecting 
warfarin metabolism
The following is a summary of possible 
factors affecting warfarin metabolism:
a) Thyroid disease: Hypothyroidism 
results in a reduced metabolic rate 
with clotting factors remaining in the 
circulation for longer and result in higher 
requirements for warfarin. When thyroid 
replacement hormones are administered, 
the metabolic rate will increase as it 
returns to normal and clotting factors 
are metabolised more rapidly. The 
requirements for warfarin thus decrease. 
Similarly, when doses of thyroxine are 
increased, warfarin requirements fall. It 
is therefore necessary to check the INR 
after –7 days, then weekly until this 
is stable. The reverse applies if doses of 
thyroxine are reduced. Hyperthyroidism 
results in an accelerated metabolic rate 
with clotting factors being cleared at 
medication.7,8  One UK study found that as 
many as 92% of patients who were taking 
herbal medications with warfarin did not 
inform a health care professional.7
Herbal medications may interact with 
warfarin as follows: 1,9-12
a) They may contain substances that have 
coumarin, salicylate or antiplatelet 
properties.  Though there have been 
no documented case reports, there is 
a theoretical risk for potentiation of 
warfarin activity (e.g., anise, chamomile, 
red clover)
b) They may interfere with haemostasis 
and platelet aggregation (e.g., feverfew, 
garlic, ginger)
c) They may be structurally similar to 
vitamin K or contain large amounts 
of vitamin K and consequently have a 
procoagulant effect (e.g., Coenzyme Q10 , 
Green tea)
d) They may interfere with metabolism of 
warfarin through inhibition or induction 
of cytochrome system (e.g., Ginseng 
and St John’s wort both inhibit the 
cytochrome P50 system)
Dietary supplementation may affect 
warfarin levels as follows:10,1,1
a) Minerals are suspected to bind to 
warfarin and therefore inhibit its 
absorption. Administration of warfarin 
should be separated from intake of these 
minerals by a period of 2 hours.
b) With the exception of vitamin K, vitamins 
are unlikely to interact unless taken at 
doses larger than the recommended daily 
dose.
c) Vitamin K directly antagonises the effects 
of warfarin. Therefore patients should 
be advised to take a vitamin K free 
preparation or be consistent in the use of 
multivitamins containing vitamin K.
Table 1 summarises some practice 
points to aid in the safe management of 
patients on oral anticoagulation who are 
also on alternative therapies. Producing 
an exhaustive reference list of interactions 
with warfarin is beyond the scope of this 
review article. The reader is provided with 
some recommended references at the end. 
Warfarin and food
Foods may affect warfarin levels 
particularly if they contain a high vitamin 
K content.15 Table 2 provides a list of such 
foods. It is important to keep in mind 
that enteral feeds may contain a large 
amount of vitamin K. Patients on weight 
reduction diets tend to have diets based 
on leafy vegetables which may contain 
large amounts of vitamin K. In such cases, 
patients should be advised to keep constant 
intakes of these foods.1,15  Alcohol may also 
Figure 1
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Summary of some factors that may affect the body’s handling of warfarin
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Table 1
Ensuring safe use of alternative medications 
1.1 Herbal medications also have the potential to interact with warfarin
1.2 Always assume an interaction occurs unless there is evidence to the contrary
1. When there is a potential for interaction:
  1..1 Patient should be advised to stop the drug before starting warfarin
  1..2 If patients insist on taking these medicines, more frequent
   INR monitoring and closer observation for signs and symptoms of
   bleeding is recommended
  1.. If a patient self-administers a remedy without advice, it is prudent to ask
   the patient to stop and recheck INR within -7 days and then at regular
   intervals until stable
1. When a documented report of interaction exists, consider the combination as
  contraindicated due to a potential risk of thrombotic complications
1.5 Ask patients about the use of alternative therapies since they often will 
  not inform you
1.6 Information is often obtained by patients through alternative sources as opposed
  to health care professionals
1.7  Patients are less likely to report adverse events from herbal interactions
1.8 Herbal products may have several common and scientific names
Table 2
Foods that may affect warfarin levels  
  
Asparagus Endive (chicory) Scallion
Avocado Green beans Soya bean products
Beef liver Green tea Spinach
Broccoli Kale Swiss chard
Brussel sprouts Lettuce (including red) Tonic water (quinine)
Cabbage (green) Liver Turnip greens
Collards (white cabbage) Mint Water cress
Coriander Parsley 
  
e) Patient concordance: Possible lack 
of patient understanding of the risks 
associated with anticoagulation therapy 
may result in patient nonconcordance 
resulting in a variable and unpredictable 
response.1,1
f) Low body weight: Increased sensitivity 
to warfarin may require reduced dosing.1
g) Malignancy:  Treatment with cytotoxic 
agents and metastases to the liver 
may lead to an increased sensitivity to 
warfarin.1
h) Congestive heart failure: Hepatic 
congestion due to heart failure may lead 
to an increased sensitivity to warfarin.1,1
Other risk factors that may result in a 
variable anticoagulation response are: 17-19
• Multiple warfarin dosage changes 
 (> changes within 6 months)*
• Inappropriate warfarin dosage change
• Addition of a new drug potential for 
interaction (short course antibiotics have 
been most often implicated)*
• Administration of multiple medications 
(>)
• Risk factors for gastrointestinal (GI) 
tract bleeding include a past history of 
gastrointestinal bleeding, concomitant 
use of conventional NSAIDs
• Comorbid conditions associated with 
higher risk for intracerebral bleeding 
– including uncontrolled hypertension 
(persistently > 160/90), cerebrovascular 
disease, head trauma, concomitant use of 
conventional NSAIDs
• Malnutrition and malabsorption
• Other decompensating systemic illness 
(especially infection, disseminated 
intravascular coagulation).
Evidence is conflicting with respect to 
patient age with some studies indicating 
an increased risk and others finding 
no association between age and oral 
anticoagulants. The risk-benefit should 
however be assessed in patients aged 
over 75.18 Patients on high intensity 
anticoagulation appear to have a higher risk 
of being out-of-control since a higher target 
INR is usually aimed for.17,18
Various studies involving retrospective 
analysis of patient data have concluded that 
mortality is lowest when the INR is within 
a faster rate. Therefore lower doses of 
warfarin are required. If antithyroid drugs 
are administered (eg propylthiouracil or 
carbimazole), the metabolic rate will slow 
down and therefore the requirements 
for warfarin will increase since clotting 
factors will remain in the blood stream 
for a longer time.1,,1,16
b) Elevated body temperature (pyrexia 
or hyperthermia): This results in an 
accelerated metabolic rate with clotting 
factors being cleared at a faster rate. 
Therefore lower doses of warfarin are 
required.1,1
c) Liver disease: This may result in various 
effects on coagulation, including vitamin 
K deficiency due to intra- or extra- 
hepatic cholestasis, reduced synthesis 
of coagulation factors due to severe 
hepatocellular damage and functional 
abnormalities of platelets and fibrinogen 
found in patients with liver failure. 
Consequently, the effects on INR are 
unpredictable and closer INR monitoring 
is required.1,1
d) Stress and grief: These have an 
unpredictable response. Patients may 
require closer monitoring in such 
situations.1,1
* Most common risk factors implicated
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the range of 2.2.-2.. An INR >6.0 indicates 
a risk of major haemorrhage in the next 1 
days despite no current signs of bleeding.20 
Adverse effects
The main adverse effects of warfarin 
are: 1,16,21
• Increased risk of bleeding which is not 
necessarily accompanied by a high INR 
and which is related to the inherent 
property of warfarin as an anticoagulant. 
Patients need to be informed about this 
risk and what action to take in case of 
bleeding.
• Skin necrosis occurs early in treatment 
especially in patients who have protein 
C or S deficiency. The latter are natural 
anticoagulants also depending on 
vitamin K for synthesis. Initial treatment 
with warfarin therefore results in a 
reduced concentration of the body’s own 
anticoagulants. In such cases, warfarin 
should be stopped and heparin started.
• ‘Purple’ toe syndrome is used to describe 
an acute digital cyanosis secondary 
to microembolism from a proximal 
atheromatous source and is common in 
patients with atherosclerotic disease such 
as diabetes mellitus, hypertension and 
peripheral vascular disease. Following 
such an episode, warfarin should be 
contraindicated. 
Other rare adverse effects include: 1,16,21
• alopecia
• urticaria, dermatitis
• nausea, diarrhoea and abdominal cramps
• anorexia
• unexplained drop in haematocrit
• jaundice, hepatic dysfunction and 
pancreatitis.
Contraindications
Contraindications (listed below) 
depend on individual circumstances and are 
seldom absolute. It is recommended that 
an individual’s risk/benefit assessment is 
performed prior to initiating warfarin, and 
then annually.1,16,19,21,22
The following may be considered as
absolute contraindications:16,19,22 
• Pregnancy. Due to the teratogenic effects 
of warfarin, patients receiving warfarin 
should be warned about the risks prior to 
conception. Patients who conceive while 
on warfarin should be advised to seek 
immediate expert help.
• Bleeding predisposition such as 
haemophilia   
• Thrombocytopenia (<50 x 10/µl) 
• Uncontrolled hypertension (>160/90). 
However, this may be considered as  
reversible if hypertension is adequately 
treated 
• Noncompliance to medication or 
monitoring.
The following may be considered as 
relative contraindications:19,22 
• Significant alcohol use (more than 28 
units per week for men; more than 21 
units for women)  
• Conventional NSAID use leading to a 
greater risk of gastrointestinal bleeding 
- this may be considered as reversible if 
replaced with alternative therapy that will 
allow the patient to take anticoagulants
• Trauma related activities.
This review summarises the numerous 
factors that may affect the body’s handling of 
warfarin. As the use of warfarin increases and 
patients’ regimens become more complex, 
maintaining patients’ blood levels within the 
therapeutic range becomes more challenging, 
with bleeding the major feared adverse 
effect to prevent. The advent of near patient 
testing with the availability of immediate 
INR results, may be the solution to making 
treatment with warfarin safer in the future. 
Annex 1
Useful sources of information  
 
Source Short Description
Stockley Drug Interactions  General information related to
– A Pharmaceutical Press Publication, 2005 anticoagulant interactions
Herbal Medications  Individual drug monographs discuss
– A Pharmaceutical Press Publication, 2005 current evidence. Particularly useful are
  Appendices 6 and 17 that refer
  specifically to oral anticoagulants
www.bnf.org Latest version of British National 
  Formulary – suitable source for 
  warfarin-drug interactions
www.mca.gov.uk Site for the Medicines and Health Care
  Regulatory Authority, UK – a useful
  source of any newly reported interactions
  between alternative therapies and
  warfarin
www.fda.gov/medwatch FDA,USA, safety information and adverse
  event reporting programme
www.drugs.com Physician’s Desk Reference Information
  requiring a free first time registration.
  Exhaustive information on warfarin
  including interactions and endogenous
  factors influencing metabolism of the
  drug
British Society of Haematology Guidelines on Oral Anticoagulation: 
www.bcshguidelines.com third edition, 1998
 
Scottish Intercollegiate Guideline Network Antithrombotic Therapy (No.6), 
www.sign.ac.uk March 1999
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Erratum
Vella V.  Drug-induced peptic ulcer disease.  Journal of the Malta College of Pharmacy Practice 2005;10:16.  The fifth sentence in 
the second paragraph under the sub-heading ‘Bisphosphonates’ should have read: Patients should be also be reminded to stand or sit 
upright for at least 0 minutes after taking the tablet.
